New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study by Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in The Journal of Clinical Investigation, found that Niagen supplementation reduced signs of inflammation, specifically inflammatory cytokin